# Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome

> **NCT02243579** · PHASE2 · COMPLETED · sponsor: **National Cancer Institute (NCI)** · enrollment: 24 (actual)

## Conditions studied

- Recurrent Mycosis Fungoides and Sezary Syndrome
- Refractory Mycosis Fungoides and Sezary Syndrome
- Stage IB Mycosis Fungoides and Sezary Syndrome AJCC v7
- Stage IIA Mycosis Fungoides and Sezary Syndrome AJCC v7
- Stage IIB Mycosis Fungoides and Sezary Syndrome AJCC v7
- Stage IIIA Mycosis Fungoides and Sezary Syndrome AJCC v7
- Stage IIIB Mycosis Fungoides and Sezary Syndrome AJCC v7
- Stage IVA Mycosis Fungoides and Sezary Syndrome AJCC v7
- Stage IVB Mycosis Fungoides and Sezary Syndrome AJCC v7

## Interventions

- **OTHER:** Laboratory Biomarker Analysis
- **BIOLOGICAL:** Pembrolizumab

## Key facts

- **NCT ID:** NCT02243579
- **Lead sponsor:** National Cancer Institute (NCI)
- **Sponsor class:** NIH
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-10-15
- **Primary completion:** 2018-01-04
- **Final completion:** 2019-04-01
- **Target enrollment:** 24 (ACTUAL)
- **Last updated:** 2019-09-20


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02243579

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02243579, "Pembrolizumab in Treating Patients With Relapsed or Refractory Stage IB-IVB Mycosis Fungoides or Sezary Syndrome". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT02243579. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*